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Abstract
Type I interferons (IFNs) are multifunctional cytokines that regulate immune responses and 
cellular functions but also can have detrimental effects on human health. A tight regulatory 
network therefore controls IFN signaling, which in turn interferes with medical interventions. The 
JAK-STAT signaling pathway transmits the IFN extracellular signal to the nucleus for alterations 
of gene expression. STAT2 is a well-known essential and specific positive effector of type I IFN 
signaling. Here, we report that STAT2 is also a previously unrecognized crucial component of the 
USP18-mediated negative feedback control in both, human and murine cells. We found that 
STAT2 recruits USP18 to the type I IFN receptor subunit IFNAR2 via its constitutive membrane-
distal STAT2 binding site. This mechanistic coupling of effector and negative feedback functions 
of STAT2 provides novel strategies in treatment of IFN signaling related human diseases.
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Introduction
Type I interferon (IFN) signaling has emerged as a highly complex regulatory network 
coordinating the host’s defense against pathogens and cancer via expression of over 300 
IFN-stimulated genes (ISGs) 1,2. Proteins encoded by ISGs include cytokines and 
chemokines that modulate innate and adaptive immune responses, enzymes that specifically 
block growth and survival of pathogens, and transcription factors and other regulators that 
affect cell proliferation and survival. Many studies from human genetic diseases and mouse 
models have demonstrated that IFNs are essential for immune responses against infections 
and cancer development 3,4. Therefore, IFNs have been successfully used to treat viral 
infections, auto-immune disorders, and cancer 5. Most recently, it has been revealed that 
autonomous IFN responses in cancer cells are required for successful anticancer therapies, 
including conventional chemotherapies, targeted anticancer treatment, radiotherapy, and 
immunotherapy 4,6. However, it is also known that high dose IFN therapies cause severe 
acute and chronic side effects 7,8. Furthermore, excess IFN production or dysregulated IFN 
signaling contributes to pathogenic process in patients with systemic lupus erythematosus, 
Sjogren’s syndrome, systemic sclerosis, rheumatoid arthritis and in the rare genetic disorders 
known as interferonopathies 9,10. Together, these findings indicate that accurate fine-tuning 
of the IFN system is crucial for human health and for therapeutic interventions.
The binding of type I IFNs to the receptor subunits IFNAR1 and IFNAR2 induces the 
activation of their associated Janus family tyrosine kinases TYK2 and JAK1, respectively 11. 
Activated TYK2 and JAK1 in turn phosphorylate IFNAR2-associated STAT2 and STAT1, 
which results in formation of the DNA binding STAT1/STAT2/IRF9 ternary complex IFN-
stimulated gene factor 3 (ISGF3). ISGF3 promotes expression of genes with the IFN-
stimulated response element in their promoters 12,13. Signaling patterns elicited by type I 
IFNs strongly depend on the cellular and physiological context 14. An intricate interplay of 
receptor dimerization dynamics and spatiotemporal modulation of IFN signaling by multiple 
positive and negative intracellular regulators 1,15 and by endocytosis 16 likely contribute to 
signaling plasticity 17. Among these regulators, the ubiquitin-specific protease USP18, 
which we identified during analysis of gene expression in a leukemia fusion protein mouse 
model 18,19, plays a most intriguing role. USP18 is an enzyme that removes an ubiquitin-like 
modifier, ISG15, from conjugated proteins 20. However, USP18 expression is strongly 
stimulated by IFN treatment and exerts negative regulation of type I interferon signaling, 
which is independent of its enzymatic activity 21. By competing with JAK1 for binding 
IFNAR2, USP18 may interfere with cytosolic stabilization of signaling complexes, which is 
likely mediated by the Janus kinases. It thereby reduces ligand binding, receptor 
dimerization and downstream signaling in a complex, IFN affinity-dependent manner 21–23. 
Interestingly, in human cells, ISG15 directly regulates USP18 stability 24. Furthermore, 
critical functions of USP18 in IFN mediated immune responses are demonstrated in mouse 
and human models 25–32 suggesting the broad impact of USP18 in immune responses and 
therapeutic potential of modulating USP18 inhibitory effects.
While quantifying effector interactions with IFNAR2 by live cell protein micropatterning 
assays, we recently observed that recruitment of STAT2 is affected by USP18 33, suggesting 
a functional crosstalk between these proteins. Among the seven mammalian STAT proteins, 
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which are activated by diverse cytokines 34, STAT2 is unique in being selectively involved in 
type I and type III IFN signaling. Here, we investigated in detail the role of STAT2 in 
IFNAR desensitization by USP18 using live cell micropatterning for real time protein 
interaction assays and single-molecule imaging in combination with protein biochemical 
approaches. We found that, beyond being a key effector of IFN signaling, STAT2 is essential 
for USP18-mediated inhibition of JAK-STAT signaling. STAT2 directly interacts with 
USP18 and thus mediates its recruitment to IFNAR2. In turn, anchored USP18 interferes 
with receptor dimerization and JAK phosphorylation. Elucidating this previously 
unrecognized requirement for STAT2 in negative feedback regulation will expand the 
potential for local or systemic modulation of IFN signaling in treating human disease.
Results
USP18 interacts with STAT2
The role of USP18 in IFN signaling is independent of its ISG15 deconjugating activity but 
relies on its interaction with IFNAR2 21,35. To identify proteins that may regulate USP18 
function in the IFN signaling pathway, we conducted a yeast two-hybrid screen using the 
wild type human, full-length USP18 and its active site mutant (C64A) as bait proteins. We 
identified 11 independent clones encoding STAT2. Likewise, direct interaction of STAT2 
and USP18 was detected in a targeted yeast two-hybrid assay (Fig. 1a). Co-
immunoprecipitation showed interaction between exogenously expressed USP18 and STAT2 
(Fig. 1b). Furthermore, a pull-down analysis revealed the direct binding of biochemically 
purified STAT2 and USP18 (Fig. 1c).
To quantify the interaction between STAT2 and USP18 in live cells, a cell micropatterning 
approach for spatially controlled immobilization of bait proteins in the plasma membrane 
via the HaloTag 33 was employed (Supplementary Fig. 1a). This technique quantifies 
equilibrium binding to a target protein within the cell in situ and thus nicely complements 
co-immunoprecipitation data with respect to their functional relevance. Co-localization of 
STAT2 and USP18 together with micropatterned IFNAR2 confirmed constitutive interaction 
of both STAT2 and USP18, with IFNAR2 (Supplementary Fig. 1b–d). Interaction dynamics 
were analyzed by fluorescence recovery after photobleaching (FRAP) revealing similar rate 
constants for STAT2 (τSTAT2: 79 s ± 28 s) and USP18 (τUSP18: 103 s ± 33 s, Supplementary 
Fig. 1e), suggesting simultaneous interaction of both proteins with IFNAR2. We next 
examined IFNAR2-independent interaction of STAT2 and USP18 in IFNAR2-deficient U5A 
cells by using cell micropatterning. A fusion protein of STAT2 with a transmembrane 
domain (TMD) as well as extracellular mTagBFP and HaloTag (HaloTag-mTagBFP-TMD-
STAT2) was used as bait (Fig. 1d). Co-expression of this construct with mEGFP-tagged 
USP18 revealed strong co-localization within micropatterns as quantified by the contrast 
between the patterned and non-patterned regions in the cells. No significant contrast was 
observed when only mEGFP was co-expressed with STAT2 as bait or when USP18 was co-
transfected with a transmembrane domain that was not fused to STAT2 (Fig. 1d, boxplot). 
Monitoring the exchange kinetics of intracellular USP18 bound to micropatterned STAT2 by 
FRAP (Fig. 1d) yielded a mean interaction lifetime of τ: 53 s ± 28 s (8 cells analyzed). 
Furthermore, using 2fTGH, MDA-MB-231, and KT-1 cells, we confirmed the interaction of 
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endogenous USP18 and STAT2 by co-immunoprecipitation assays (Fig. 1e). Together, these 
different approaches clearly established that STAT2 directly binds to USP18.
STAT2 is required for USP18-mediated inhibition of type I IFN signaling
To examine the role of STAT2 in USP18-mediated desensitization of type I IFN signaling, 
we employed U series cell lines derived from human fibrosarcoma 2fTGH cells, U1A 
(TYK2−/−), U2A (IRF9−/−), U4A (JAK1−/−), U5A (IFNAR2−/−), and U6A (STAT2−/
−) 36,37. These cells were stably transduced with the MIP control or MIP-USP18 (Fig. 2a–e). 
As expected, in cells lacking TYK2 (U1A), JAK1 (U4A), and IFNAR2 (U5A), 
phosphorylation of STAT1 was not observed after IFNα treatment (Fig. 2b, 2d, and 2e) since 
important components of the signaling pathway were missing. In 2fTGH and U2A cells, 
USP18 expression clearly reduced STAT1 phosphorylation upon IFNα treatment (Fig. 2a 
and 2c), indicating that USP18 inhibits IFN signaling upstream of IRF9, as reported 
previously 21. Interestingly, expression of USP18 did not affect STAT1 phosphorylation in 
STAT2 deficient U6A cells (Fig. 2f), suggesting that STAT2 is required for USP18-mediated 
inhibition. It should be noted that IFN-induced STAT1 phosphorylation was much weaker in 
U6A cells than in 2fTGH cells, since STAT2 supports STAT1 phosphorylation (Fig. 2g) 38. 
To further verify the critical role of STAT2, we used murine embryonic fibroblasts derived 
from Stat2 knockout mice (Stat2−/− MEF). In these cells, ectopic Usp18 did not exert an 
inhibitory effect on IFNβ-induced STAT1 phosphorylation (Fig. 2h, lanes 1–4). STAT2 
transduction strongly increased IFNβ-stimulated STAT1 phosphorylation, but in this context 
ectopic USP18 exerted a strong inhibitory effect (Fig. 2h, lanes 5–8). These results indicate 
that, in addition to physically interacting with USP18, STAT2 plays a critical role in 
mediating the negative effect of USP18 on Type I IFN signaling.
To investigate whether the inhibitory effect of STAT2 plus USP18 can be detected upstream 
of STAT1 phosphorylation, we examined JAK1 phosphorylation. Exogenously expressed 
USP18 did not affect JAK1 phosphorylation in Stat2−/− MEFs, but clearly diminished JAK1 
phosphorylation in Stat2-transduced Stat2−/− MEFs (Fig. 2i), indicating that STAT2 is 
critical for USP18-mediated inhibition of JAK1 phosphorylation. To confirm this finding, we 
also selected an effective Stat2 shRNA to knockdown Stat2 expression (Fig. 2j). Neither 
control shRNA nor Stat2-specific shRNA affected IFNβ-induced JAK1 phosphorylation in 
Usp18−/− primary murine bone marrow cells (Fig. 2k). In contrast, expressing a Stat2 
shRNA, but not a control shRNA, abolished the negative effect of exogenously expressed 
USP18 on JAK1 phosphorylation. These results further support that STAT2 is required for 
USP18-mediated inhibition, which is upstream of STAT phosphorylation.
To further examine the mechanistic requirement for STAT2 in USP18-dependent negative 
regulation of IFN signaling we examined expression of 23 IFN-inducible genes in Stat2−/− 
MEFs transduced with control- or Usp18- expression vectors, and with or without 
exogenous reintroduction of Stat2. As expected, the majority of genes tested (21 of 23) were 
not induced by IFN treatment in the absence of STAT2 (representative genes shown in 
Supplementary Figure 2a). We did, however, identify two genes (Irf9 and Cxcl9) that 
showed weak induction of expression in the absence of STAT2 (Supplementary Figure 2b). 
Importantly, USP18-mediated inhibition of gene expression for these ISGs was only 
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observed upon reintroduction of STAT2 (Supplementary Figure 2a and 2b). These 
observations fully support the essential biological role of STAT2 for IFN-responsive signal 
transduction 39. Furthermore, both of our biochemical and gene expression analyses 
demonstrate the mechanistic requirement for STAT2 in USP18-mediated inhibition of 
interferon signaling.
Both coiled-coil (CC) and DNA binding (DB) domains of STAT2 are involved in STAT2 
interaction with USP18
Structurally, STAT2 can be divided into N-terminal (NTD), coiled-coil (CC), DNA binding 
(DB), linker domain (LD), Src homology 2 (SH2) dimerization, and C terminal 
transactivation domains (Fig. 3a). In this study, we included the linker domain in DB, since 
it has been reported that the linker domain is required for the appropriate DB structure 40. To 
understand the mechanism of STAT2 in USP18-mediated inhibition of IFN signaling for 
potential therapeutic applications, we performed co-immunoprecipitation assays using a set 
of STAT2 deletion mutants (Fig. 3a). FLAG-tagged USP18 (FLAG-USP18) was coexpressed 
with Myc-tagged STAT2 (STAT2-Myc) or either of three fragments of STAT2 (aa 1-136 of 
NTD, aa 139-572 with CC and DB domains, and aa 573-861 containing SH2 and 
transactivation domains). NTD and the C-terminal region of STAT2 did not co-precipitate 
with USP18. However, the protein with only CC and DB domains of STAT2 significantly 
interacted with USP18 (Fig. 3b). Furthermore, using USP18 and additional mutants of 
STAT2, immunoprecipitation of either USP18 (Fig. 3c) or STAT2 (Fig. 3d) revealed that the 
CC-only or DB-only-deleted STAT2 were able to associate with USP18. However, deletion 
of both CC and DB domains of STAT2 led to a loss of co-precipitation with USP18. Thus, 
results from this series of interaction analyses suggest that both CC and DB domains of 
STAT2 contribute to its interaction with USP18.
Coiled-coil and DNA binding domains of STAT2 are important for USP18-mediated 
inhibition of type I IFN signaling
To examine the role of the STAT2-USP18 interaction in negative feedback regulation of IFN 
signaling, we expressed in U6A cells an empty vector control, full length STAT2, or deletion 
mutants of STAT2. USP18 expression reduced STAT1 phosphorylation in STAT2 expressing 
U6A cells (Fig. 4a). Furthermore, the negative effect of USP18 was detected in the presence 
of STAT2 lacking the CC domain (Fig. 4b) or the DB domain (Fig. 4c). In contrast, although 
STAT2 lacking both CC and DB domains still promoted IFNα-induced STAT1 
phosphorylation, it did not support the inhibitory function of USP18 (Fig. 4d), suggesting 
that the interaction of these two proteins via CC and DB domains of STAT2 is crucial for the 
effect of USP18 on IFN signaling. Importantly, expression of USP18 and different STAT2 
constructs did not affect cell surface levels of the IFN receptor subunits IFNAR1 and 
IFNAR2 in these cell lines (Fig. 4e).
The N- and C-terminal regions of USP18 bind to STAT2 and IFNAR2 and are important for 
inhibiting the IFN response
Based on our previous report 21 and the results presented above, USP18 interacts with both 
IFNAR2 and STAT2. We therefore assessed which regions of USP18 were required for its 
interaction with STAT2 and IFNAR2. We generated six constructs for expression of selected 
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regions of USP18 (Supplementary Fig. 3a and 4a). When co-immunoprecipitation assays 
were conducted with cell lysates containing FLAG-tagged USP18 and Myc-tagged STAT2, 
aa 1-112, 51-242, 1-242, and 243-312, but not aa 113-242 and 313-372 of USP18 interacted 
with STAT2, suggesting that aa 51-112 and 243-312 of USP18 are two important regions for 
the STAT2-USP18 interaction (Supplementary Fig. 3b). Further analysis revealed that aa 
303-312 of USP18 interacted with STAT2 (Supplementary Fig. 3c). Consequently, an aa 
303-312 deletion mutant of USP18 (USP18Δ303-312) was unable to suppress IFNα-induced 
STAT1 phosphorylation (Supplementary Fig. 3d).
We also established human KT-1 cell lines stably expressing wild-type USP18 or the non-
interacting mutant USP18Δ303-312. Upon addition of IFNα, cells expressing wild-type 
USP18-showed strong inhibition of phosphorylation of JAK1 and STAT1. USP18Δ303-312 
did not show such a negative effect (Supplementary Fig. 3e), in agreement with its loss of 
STAT2 interaction.
Regarding USP18 and IFNAR2 interaction, peptides comprising aa 1-112, 1-242, and 
313-372, but not aa 51-242, 113-242, and 243-312 of USP18 co-immunoprecipitated with 
the intracellular domain (ICD) of IFNAR2 (Supplementary Fig. 4b). These results suggest 
that aa 1-51 and aa 313-372 of USP18 are important for the IFNAR2-USP18 interaction. 
Further analysis narrowed the first interaction domain to aa 36-51 of USP18 (Supplementary 
Fig. 4c and 4d). In line with this result, expression of aa 36-372, but not aa 51-372, of 
USP18 inhibited STAT1 phosphorylation upon IFNα treatment (Supplementary Fig. 4e). 
Taken together, these findings indicate that aa 36-51 and 313-371 of USP18 are critical for 
the USP18-IFNAR2 interaction and that aa 51-112 and 303-312 of USP18 are important for 
the USP18-STAT2 interaction. We therefore conclude that the N- and C-terminal regions (aa 
36-51 and 317-371) of USP18 play important roles in the interaction with IFNAR2, and the 
adjacent regions (aa 51-112 and 303-312) are critical for USP18 binding to STAT2.
STAT2 recruits USP18 to IFNAR2
These results established that USP18 independently interacts with IFNAR2 and STAT2. 
Since STAT2 itself constitutively interacts with IFNAR2 33,41,42, we aimed to further 
examine whether interaction between USP18 and IFNAR2 was affected by STAT2. In 
STAT2-deficient U6A cells, the USP18-IFNAR2 interaction was up to 10-fold enhanced 
upon expression of STAT2 (Fig. 5a). The importance of STAT2 for USP18 recruitment could 
also be verified by live cell micropatterning: while no binding of USP18 to micropatterned 
IFNAR2 was detectable in U6A cells, a strong increase in contrast after complementation 
with STAT2 was observed (Fig. 5b and 5c). In HeLa cells, the endogenous expression level 
of STAT2 was sufficient to yield significant binding of USP18 bound to micropatterned 
IFNAR2 (Supplementary Fig. 5c). However, substantially increased USP18 binding was 
observed upon ectopic co-expression of STAT2. These results highlight the critical role of 
STAT2 concentration in effective recruitment of USP18 to IFNAR2. In absence of STAT2 
binding of USP18 was weakened such as no significant recruitment of USP18 to 
micropatterned IFNAR2 was detectable in this experimental system. A comparable loss in 
USP18 binding to IFNAR2 was obtained in presence of STAT2 upon deletion of the STAT2 
binding site on IFNAR2, which was suggested to include at least amino acids 418-444 41. 
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The recruitment of STAT2 and USP18 to IFNAR2, C-terminally truncated at position 375, 
was strongly reduced (Fig. 5d and Supplementary Fig. 5c). Mapping the STAT2 and USP18 
binding to IFNAR2 by cell micropatterning of further deletions and mutations 
(Supplementary Fig. 5d–f) confirmed aa 418-444 of IFNAR2 as a minimal interaction site 
for STAT2 and USP18. These results established that the interaction of USP18 and STAT2 is 
responsible for recruitment of USP18 to IFNAR2 and is critical for the negative effect of 
USP18 on type I IFN-induced JAK1 phosphorylation (Fig. 2i–k), which is upstream of type 
I IFN-induced STAT1 activation.
STAT2-USP18 interaction regulates ternary complex assembly of the type I IFN receptor
We recently reported that human USP18 negatively regulates the binding affinity of type I 
IFNs to their cell surface receptor, thus reducing the responsiveness of IFN-primed cells to 
subsequent IFN stimulation 22,23. Quantitative single molecule dimerization assays revealed 
that USP18 interferes with the assembly of the ternary IFN/IFNAR1/IFNAR2 complex, 
which explains the loss in ligand binding affinity 22. To explore whether the STAT2-USP18 
interaction is important for the effect of USP18 on ligand binding and ternary complex 
formation, ligand binding assays in U6A cells were performed. To this end, we quantified at 
a single molecule level the binding of IFNα2 M148A labeled with DY647 (DY647IFNα2 
M148A). This ligand requires simultaneous interaction with both IFNAR1 and IFNAR2 for 
binding to the cell surface receptor and thus indirectly probes ternary complex 
formation 22,43. In contrast to previous experiments performed in HeLa or IFNAR2-deficient 
U5A cells 22, no substantial difference in the amount of DY647IFNα2 M148A bound to the 
cell surface receptor was detected in U6A cells that express USP18 (Fig. 6a and 6b). This 
experiment suggests impaired negative regulation by USP18 in absence of STAT2. By 
contrast, complementation by co-expression of STAT2 significantly decreased the 
number DY647IFNα2 M148A on the cell surface as expected for effective desensitization by 
USP18. Complementation with transiently transfected STAT2, without USP18, had no effect 
on ligand binding. For both, CC-DB and CC fragments of STAT2 a significant support of 
USP18-mediated negative regulation of ternary complex formation, confirming the relevance 
of the STAT2-USP18 interaction for inhibiting IFNAR assembly. These results corroborate 
that the presence of both proteins, STAT2 and USP18, is required for USP18-mediated 
inhibition of ternary complex formation at the plasma membrane.
Furthermore we analyzed the effective cell surface binding affinity of FITC-labeled IFNα to 
cell surface IFNAR by flow cytometry. FITC-labeled IFNα showed concentration-dependent 
binding to 2fTGH cells, but did not bind to IFNAR2-deficient U5A cells (Supplementary 
Fig. 6a and 6b). FITC-labeled IFNα had similar biological activity to non-labeled IFNα 
(Supplementary Fig. 6c). These results demonstrate that FITC-labeled IFNα is suitable for 
testing the IFN-receptor interaction. We ectopically expressed USP18, STAT2, and 
STAT2ΔCC/DB, which loses its USP18-binding ability (Fig. 3), in U6A cells. USP18 
decreased IFNα binding to U6A cells only in the presence of full length STAT2 but not 
STAT2ΔCC/DB (Fig. 6c), supporting the notion that interaction of STAT2 and USP18 is 
important for the type I IFN ligand-receptor binding. Phosphorylation of tyrosine (Y) 690 in 
STAT2 is not only critical for ISGF3 formation and ISG regulation, but also for STAT2-
mediated STAT1 phosphorylation 44. Accordingly, expression of the STAT2 mutant Y690F 
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in U6A cells did not enhance IFNα-induced STAT1 phosphorylation (Fig. 6d). Since the 
STAT2-USP18 interaction is not affected by this mutation (Supplementary Fig. 6d), USP18 
expression still reduced phosphorylation of STAT1 in STAT2 Y690F-expressing U6A cells 
stimulated with IFNα (Fig. 6d). Importantly, expression of USP18 also decreased the level 
of IFNα binding to STAT2 Y690F-expressing U6A cells (Fig. 6e). Together, these results 
establish that the interaction between USP18 and STAT2 mediates the inhibitory effect of 
USP18 on type I IFN receptor assembly and signaling. Our data suggest that USP18 is 
recruited to IFNAR2 via its interaction with the STAT2 CC and DB domains to allow an 
additional interaction of USP18 with the membrane-proximal domain of IFNAR2 (Fig. 6f), 
which probably causes JAK1 dissociation 21.
Targeted disruption of the STAT2-USP18 interaction enhances IFN-dependent response
IFNs modulate crucial immune responses during pathogen infection and against malignant 
cells, which are effectively abrogated by expression of USP18. Therefore, we next examined 
whether a peptide comprising the STAT2 CC and DB domains can block the USP18-STAT2 
interaction and thus maintain IFN signaling responses in presence of USP18. To this end, 
STAT1, USP18, and the STAT2 CC/DB fragment were co-expressed in HEK 293T cells 
(Fig. 7a). As expected, STAT2 CC/DB counteracted the negative effect of USP18, resulting 
in increased STAT1 phosphorylation.
It is known that the CC domain of STAT2 interacts with IRF9 and that the DB domain of 
STAT2 is essential for activation of ISG transcription 45,46. Although expression of STAT2 
CC/DB can successfully disrupt the STAT2-USP18 negative feedback interaction, it may 
also compete with wild-type STAT2 in the formation of the ISGF3 complex and in the 
binding to ISRE promoter regions upon nuclear translocation. To investigate these 
downstream biological functions, we generated a triple mutant within STAT2 CC/DB, 
carrying the exchanges L227A, R409A, and K415A (further designated as STAT2 CC/DB 
3A). The single L227A point mutation substantially reduced interaction of STAT2 CC/DB 
with IRF9 (Supplementary Fig. 7a). Furthermore, it has been reported that the residues R409 
and K415 are important for nuclear translocation 47. STAT2 CC/DB 3A is therefore expected 
to be primarily cytosolic and to lack its ability to bind to IRF9. Yet, STAT2 CC/DB 3A 
retained its ability to disrupt the USP18 inhibitory effect on STAT1 phosphorylation (Fig. 7a, 
right lane). In addition, STAT2 CC/DB 3A, but not STAT2 CC/DB, partially blocked the 
effect of USP18 on transcription of ISGs, such as GBP1 and IFIT1 (Fig. 7b and 
Supplementary Fig. 7b). Both IFNα and IFNβ are known to promote apoptosis of several 
cancer cell lines 48. IFNα or IFNβ treatment induced apoptosis in the human myeloid cell 
line THP-1, and this effect was significantly enhanced upon addition of STAT2 CC/DB 3A 
(Fig. 7c and Supplementary Fig. 7c).
Since we identified the critical region for the USP18 interaction with STAT2 
(Supplementary Fig. 3c), we also examined whether a peptide comprising USP18 aa 
302-313 could have a similar effect as STAT2 CC/DB domains. IFN-induced STAT1 
phosphorylation in THP-1 and KT-1 cells treated with this peptide was enhanced and 
prolonged as compared to the control (Fig. 7d). Consistent with these results, we observed 
enhanced GBP-1 expression and increased apoptosis in THP-1 and KT-1 cells treated with 
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the USP18 aa 302-313 peptide (Fig. 7e and Supplementary Fig. 7d). Taken together, our 
results demonstrate that, by interfering with the USP18-STAT2 interaction, USP18-mediated 
inhibition of the type I IFN signaling can be suppressed. This implicates that the STAT2-
USP18 interaction interface could be a useful drug target for enhancing type I IFN 
responses.
Discussion
Type I IFNs are involved in a variety of different processes of innate and adaptive immune 
responses 49,50, which are coordinated by a highly fine-tuned regulatory signaling network 1. 
Unraveling the molecular and cellular determinants governing this network will be 
imperative for a better understanding and for therapeutically manipulating immunological 
responses in a variety of disease contexts. A critical role of negative regulators in type I IFN 
signaling is emerging15, which have been targeted by inhibitors to enhance IFN response: 
PKD2 exerts negative feedback via IFNAR1 51, but the PKD inhibitor CID755673 only 
slightly prolonged the IFN response. SOCS1 and SOCS3 inhibit tyrosine phosphorylation 
and nuclear translocation of STAT1 by binding to JAKs 52. However, inhibition of SOCS1 
only transiently enhances the IFN response, since it is expressed in the early phase after type 
I IFN treatment and undetectable later on 53. Additionally, SOCS1 affects not only type I but 
also type II IFN signaling. In contrast, inhibition of USP18 leads to enhanced type I IFN 
signaling at the early stage 21 and produces a prolonged response at the later stage 27,54. 
Therefore, we aimed to explore the specific mechanism of signal inhibition by the STAT2-
USP18 negative feedback interaction.
STAT2 is well known as an unique effector of type I and type III IFN signaling not only by 
being an integral component of the ISGF3 complex responsible for the induction of 
ISGs, 55,56, but also by positively regulating STAT1 phosphorylation 38,57. The biological 
significance of STAT2 in type I IFN signaling has been further corroborated by the study of 
STAT2-deficient humans and mice, which become immune compromised and are vulnerable 
to viral infection 39,58. However, for the first time, we here demonstrate that USP18 requires 
STAT2 for exerting its inhibitory effect on IFN signaling. USP18 reduced IFN binding and 
receptor dimerization as well as JAK1 phosphorylation only when STAT2 was present. 
These observations established the key role of STAT2 in USP18-mediated inhibition of IFN 
signaling and moreover suggest that the increased STAT2 levels induced by IFN signaling 
may further enhance negative feedback by USP18.
In order to fulfill its inhibitory function, USP18 needs to be recruited to the receptor 21. 
Previously, we reported that USP18 interferes with the recruitment of IFNAR1 to the IFN-
IFNAR1-IFNAR2 ternary complex, by an unknown mechanism 22. Here, we have 
demonstrated that STAT2 acts as an adaptor for recruiting USP18 to IFNAR2 via its 
membrane-distal constitutive binding site for STAT2. Binding of STAT2 and USP18 to 
IFNAR2 is synergistic, in line with the previous observation that the STAT2-IFNAR2 
interaction was strengthened by USP18 33. Hence, through stabilizing the interaction 
between STAT2 and IFNAR2, USP18 may also negatively regulate the STAT 
phosphorylation process by decreasing the STAT phosphorylation turnover rate and the 
activation of the ISGF3 complex. We assume that recruitment of USP18 to IFNAR2 via 
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STAT2 promotes the otherwise weak interaction of USP18 with a membrane-proximal site 
of IFNAR2. We previously have shown this interaction to compete with JAK1 binding, thus 
effectively reducing ternary complex formation and signal activation at the plasma 
membrane, which probably are the main inhibitory functions of USP18 21–23. Here, we 
found that STAT2 interacted with the N- as well as the C-terminal regions of USP18. 
Consistent with previous results 21, our experiments confirmed that the N- and C-terminal 
regions of USP18 directly interact with IFNAR2. Taken together, our data suggest that 
USP18 simultaneously interacts with IFNAR2 via STAT2 in the membrane distal region and 
directly in the membrane-proximal region (Fig. 6f).
Both the CC and DB domains of STAT2 are critical for the interaction with USP18 and for 
USP18-mediated negative feedback regulation of type I IFN signaling, as measured by type I 
IFN binding and STAT phosphorylation. Interestingly, these domains are also critical for the 
STAT2 interaction with IFNAR2, which can explain the binding synergy and moreover 
tightly couples STAT2 and USP18 functions. Indeed, we could demonstrate that a construct 
containing only the STAT2 CC/DB has an inhibitory effect on the function of USP18 and 
thus increases STAT1 phosphorylation. Notably, our study uncovers that a USP18 302-313 
peptide can disrupt the USP18-STAT2 interaction interface. Both peptides significantly 
enhanced IFN-triggered responses. It should be noted that, while this inhibitory effect is 
strong, it is not complete, indicating either the existence of other factors involved or that 
there is a room for improving these inhibitors. Further studies will be required for unraveling 
the STAT2 CC/DB and USP18 302-313 inhibitory effect on USP18 function including a 
structural analysis using purified proteins when they become available. Thus, novel 
strategies to manipulate negative feedback by USP18 by means of small molecule PPI 
modulators, which are currently emerging 59, can be envisaged.
Importantly, USP18 has a negative role not only in type I but also in type III IFN 
signaling 60, which also involves STAT2. Therefore, a similar mechanism of negative 
regulation by USP18 and STAT2 in type III IFN signaling can be expected. Indeed, 
preliminary data from our laboratory show that USP18 can bind to type III IFN receptor 
IL-28RA, and has no inhibitory effect on type III IFN signaling in U6A cells (Arimoto et al. 
unpublished data). Although our current functional peptide studies presented in figure 7 still 
lack in vivo validation, it is tempting to speculate that the tight functional linkage of STAT2 
and USP18 has evolved to warrant efficient control of ISGF3-based gene expression. Design 
of modulators for controlling the USP18-STAT2 interaction could therefore yield the ability 
to enhance or diminish type I and type III IFN responses in therapeutic settings.
Online Methods
Yeast two-hybrid screen
cDNA encoding full length human USP18 (wild-type and C64A mutated form) were cloned 
into the LexA DNA-binding domain plasmid derived from pBTM116 and used as bait in 
yeast two-hybrid screens of a human placental cDNA library (complexity of 106 colonies) as 
previously described 61. A total of 11 independent clones displaying similarity to STAT2 
proteins were isolated.
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Yeast two-hybrid assay
To confirm specific interactions, the following yeast two-hybrid vectors were created in this 
work, which employ the Gal4 DNA-binding and activation domains: pGBD-C1 (vector), 
control), and DNA-binding domain fusions pJJH1722 (pGBD-STAT2) and pJJH1719 
(pGBD-USP18); as well as pGAD424A (vector), control), and pJJH1721 (pGAD-STAT2) 
and pJJH1720 (pGAD-USP18) for expression of activation domain fusion proteins. 
Complete sequences of these plasmids are available upon request. For two-hybrid analyses 
with these constructs the S. cerevisiae strains pJ69-4a and pJ69-4alpha were used 62. 3 μl of 
overnight cultures from strains pJ69-4a/pJ69-4alpha carrying two-hybrid plasmids with the 
indicated coding sequences were spotted onto selective media for plasmid maintenance and 
incubated for 10 days.
Plasmid construction
Human STAT2 and its mutant cDNAs were cloned into pcDNA3.1 vector. Human STAT2 
was also cloned into pCAG and GST (6p-1) vector. Murine Stat2 was cloned into MSCV-
IRES-Puro (MIP) retroviral vector. shRNA plasmids (pLKO.1 vectors) for mouse Stat2 
(TRCN0000081538-0000081542) and control were purchased from Dharmacon.
Human USP18 and its mutant cDNAs were cloned into pcDNA3.1, pCMV7.1 3 × FLAG, 
pEGFP-C1, and MIP vector. Murine Usp18 was cloned into pCX4-bsr retroviral vector. 
Plasmid encoding human IFNAR2 in the pcDEF3 vector was kindly provided by Dr. Sergei 
Kotenko. Human IFNAR2 was also cloned into pCAG and pEBG vector.
Monomeric GFP, human STAT2-mEGFP and human mEGFP-USP18 fusion constructs (kind 
gift from Sylvie Urbé, Liverpool 63) were cloned into the plasmid vector pSEMS-26m 
(Covalys) for expression in mammalian cells. Monomeric EGFP was obtained by the A206K 
mutation within the EGFP sequence of pEGFP-N1 (Clontech). An artificial transmembrane 
domain (TMD) with the sequence ASALAALAALAALAALAALAALAKSSRL (ALA7) 
(as described by 64) extracellular fused to HaloTag (Promega) and mTagBFP (obtained from 
Vladislav Verkhusha, New York 65) and intracellularly fused to human STAT2 was cloned 
into pDisplay™ (Invitrogen). For cloning of pSEMS-HaloTag®-IFNAR2, the gene coding 
for the HaloTag followed by the genes of full length IFNAR2 or IFNAR2Δ375 without the 
N-terminal signal sequences were inserted into pDisplay (Invitrogen). The constructs 
including the Igκ signal sequence from the pDisplay vector were transferred by restriction 
with EcoRI and NotI into pSems-26m. The genes for mTagBFP, HaloTag and IFNAR2 were 
inserted into pDisplay™ –HaloTag to generate the construct pDisplay-HaloTag-mTagBFP-
IFNAR2.
Cell culture and primary bone marrow cells from Usp18−/− mice
HEK293T (ATCC), Hela (ATCC), MDA-MB-231 (kindly provided by Dr. David Cheresh, 
previously), Stat2−/− MEFs (kindly provided by Dr. Adolfo Garcia-Sastre), and U series 
(2fTGH, U1A, U2A, U4A, U5A, and U6A) (kindly provided by Dr. George Stark) cells 
were grown in DMEM medium supplemented with glutamine, penicillin/streptomycin, and 
10% FBS. THP-1 (ATCC) and KT-1 cells (kindly provided by Dr. Shigeru Fujita, 
previously) were grown in RPMI medium supplemented with glutamine, penicillin/
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streptomycin, and 10% FBS. Ba/F3 cells were grown in RPMI1640 medium supplemented 
with 15% FBS and 5% conditional media from WEHI-3B cells (kindly provided by Dr. 
Carrie Dolman, previously). Bone marrow cells from Usp18−/− 66 mice were grown in 
RPMI1640 medium supplemented with 20% FBS and IL3 and SCF conditional media. Hela 
and U series cells are routinely tested for mycoplasma. All the procedures for Usp18−/− 
mice experiments were approved by the UCSD institutional animal care and use committee
Transfection, and lentivirus or retrovirus infection
Transfection was conducted by using PEI (Polyethylenimine) 67. For the retrovirus or 
lentivirus production, 293T cells were co-transfected with plasmids encoding viral vectors 
and packaging vectors pCL-10A1 for human or Ecopac for murine cells. Viral particles were 
collected 48 h after transfection, filtered with 0.45 μm sterile filter. For the retrovirus or 
lentivirus infection, spin infection (2000g, 3hours, 30°C; Allegra X12R (Beckman Coulter)) 
in the presence of polybrene (8ug/ml) was performed.
Reagents and antibodies
Antibodies were commercially purchased as followed; anti-phospho-JAK1 (Tyr1022/1023) 
(Cell Signaling), anti-JAK1 (Cell Signaling), anti-phospho-STAT1 (Tyr 701) (Cell 
Signaling), anti- STAT1 (Cell Signaling), anti-STAT2 (Santa Cruz), anti-green fluorescent 
protein (anti-GFP), and anti-tubulin (Sigma). Antibodies against FLAG (anti-FLAG; M2), 
Myc (9E10), and hemagglutinin (HA) (12CA5 or 3F10) were purchased from Sigma, Santa 
Cruz, and Roche, respectively. Anti-IFNAR1 antibody was provided from Biogen Idec. 
Anti-IFNAR2 FITC was purchased from Sino Biological Inc. Anti-USP18 antibody is 
described as before 68. Recombinant human IFNβ was provided from Biogen Idec. 
Recombinant human IFNα, mouse IFNβ, and human IFNλ were purchased from Peprotech. 
Recombinant IFNα2 and the mutant IFNα2-M148A used in cellmicropatterning and single 
molecule assays was produced in E. coli and purified as described before 69. For site-
specifically fluorescent labeling, IFNα2 and the mutant IFNα2-M148A fused to an N-
terminal ybbR-tag were produced in E. coli and conjugated with DY 647 as described 
previously 70. A degree of labeling >90% was obtained as determined by UV/Vis 
spectroscopy.
The RGD peptide Ac-CGRGDS-COOH was custom synthesized by Coring System 
Diagnostix, Gernsheim/Germany. Poly-L-lysine (PLL) hydrobromide (Mw: 15,000–30,000 
g/mol) was purchased from Sigma Aldrich. Homobifunctional dicarboxy-PEG (COOH-
PEG3000-COOH, Mw of PEG: 3000 g/mol) was from Rapp Polymere, Tübingen/Germany. 
Poly-L-lysine graft modified with Methoxy-PEG (Mw: 2000 g/mol) (PLL-PEG-OMe) was 
purchased from SuSoS AG, Dübendorf/Switzerland. HaloTag®-O2-amine ligand (HTL) was 
purchased from Promega. Dimethylformamide (DMF), N-Ethyldiisopropylamine (DIPEA), 
N,N′-Diisopropylcarbodiimide (DIC), N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide 
hydrochloride (EDC) were purchased from Sigma Aldrich.
Synthesis of functionalized poly-L-lysine-graft-(polyethylene glycol) copolymer (PLL-PEG 
derivatives, PLL-PEG-HTL and PLL-PEG-RGD) was carried out as described recently 71.
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RNA isolation and qRT-PCR analysis
RNA was extracted with Trizol (Thermo Fisher Scientific). For qRT–PCR analyses, equal 
amounts of RNA were reverse-transcribed by qScript (Quanta Biosciences) and the resulting 
cDNA templates were subjected to qRT-PCR using KAPA SYBR FAST universal qPCR kit 
(Kapa Biosystems, Inc. Wilmington, MA) and CFX96 thermal cycler (BIO-RAD).
Primer sequences for are as follows;
RT- Isg15 -Fw; GAC TAA CTC CAT GAC GGT G
RT- Isg15 -Rev; AAC TGG TCT TCG TGA CTT G
RT- Gbp1 -Fw; GGA GGC CAT TGA GGT CTT CAT
RT- Gbp1 -Rev; CAA AGG CAT CTC GTT TGG CT
RT- Cxcl9 -Fw; TCCTTTTGGGCATCATCTTCC
RT- Cxcl9 -Rev; TTTGTAGTGGATCGTGCCTCG
RT- Irf9 -Fw; GCCTTTGCCCCATCCCCATCTC
RT- Irf9 -Rev; CCCCTGGCCCTGGAAGTACTGG
RT- Ifit1 -Fw; TGGCGACCTGGGGCAACTGTG
RT- Ifit1 -Rev; TGGGCTGCCTGTTTCGGGATGTC
RT- Igtp -Fw; CGCCTCATCAGCCCGTGGTCTAA
RT- Igtp -Rev; TGCCATTGCCAGAGTCCCCAGTC
RT-GBP1 -Fw; CCAGTTGCTGAAAGAGCAAGAGA
RT-GBP1 -Rev; TCCCTCTTTTAGTAGTTGCTCCTGTT
RT- IFIT1 -Fw; AAGGCAGGCTGTCCGCTTA
RT- IFIT1 -Rev; TCCTGTCCTTCATCCTGAAGCT
Western blotting
Western blotting was performed as previously described in detail 72. All samples were 
denatured in 1 × sample buffer [50 mM Tris-HCl (pH 6.8), 2% SDS, 2-mercaptethanol, 10% 
glycerol, and 1% bromophenol blue] for 5 min at 100 °C. Cells were lysed in RIPA buffer 
composed of 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% 
SDS, 1% Nonidet P-40 and 0.5% sodium deoxycholate. To analyze immune-complexes for 
co-immunoprecipitation assay, cells were lysed in binding buffer containing 25 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA and 0.5% Nonidet P-40 for 
coimmunoprecipitation assays. The cell lysates were centrifuged (15,000 × rpm) at 4°C for 5 
min. All lysis buffers in this study contain proteinase and phosphatase inhibitors (Roche). 
Soluble fractions were precleared by Protein G-Sepharose at 4°C for 15 min. Precleared cell 
lysates were immunoprecipitated for 1~4 hours with the indicated antibodies. 
Immunocomplexes were adsorbed to the protein G-Sepharose and, after three washes, were 
eluted by boiling for 5 min. FLAG-tagged proteins were immunoprecipitated with anti-
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FLAG M2-agarose (Sigma). All assays were performed two to four times and representative 
blots were presented. All source data for the western blots are available in the supplementary 
data set 1. For the quantification, signals were detected with the LI-COR Odyssey system.
Cell micropatterning
Micropatterned surfaces were fabricated by microcontact printing. Poly(dimethylsiloxane) 
(PDMS) stamps was generated from basic elastomer (Sylgard 184, Dow Chemicals) mixed 
with curing agent (Dow Chemicals) in a 10:1 ratio, and applied to a silicon master at 80°C 
overnight. The silicon master containing an array of lines with a width of 5 μm, a spacing of 
10 μm and a depth of 3 μm was generated by photolithography using a custom designed 
beam mask (nb technologies GmbH).
Standard glass coverslides for fluorescence microscopy were cleaned in a plasmacleaner for 
10 minutes, followed by inking of the stamp with 0.5mg/ml PLL-g-PEG-HTL in PBS buffer 
for 10 minutes. For PLL-g-PEG-HTL transfer, stamps were placed onto the glass coverslides 
for 10 minutes to generate HTL patterns. After removing the stamps, the coverslides were 
incubated with a mixture of 0.002mg/ml PLL-g-PEG-RGD and 0.1mg/ml PLL-PEG-MeO in 
PBS buffer for 1 minute to backfill the uncoated area and to allow cell adhesion. The surface 
was then rinsed in MilliQ water and dried with N2.
For cellular micropatterning, cells were cultivated at 37°C and 5% CO2 in MEM 
supplemented with 10% fetal calf serum (MEM/FCS) 1% Hepes buffer and 1% non-
essential amino acids. For transfection, cells were plated in 60 mm cell culture dishes to a 
density of approximately 50% confluence. One day after seeding, cells were transfected via 
calcium phosphate precipitation as described earlier 73. After 24–36 hours cells were plated 
on chemically modified cover glasses for 15–20 hours with medium containing penicillin 
and streptomycin (PAA). For labeling of micropatterned IFNAR, cells were incubated in 
presence of 10 nM fluorescently labeled interferon coupled to ATTO655 (AT655IFNα2).
Fluorescence imaging
Total internal reflection fluorescence microscopy (TIRFM) was performed using an inverted 
microscope microscope (Olympus IX81) equipped with a 4-line TIRF condenser (Olympus 
cell^tirf MITICO), a back-illuminated electron multiplied (EM) CCD camera (C9100-13, 
512×512 pixel from Hamamatsu) as well as lasers at 405 nm (100 mW), 488 nm (150 mW), 
561 nm (150 mW) and 640 nm (140 mW). A 60× objective with a numerical aperture of 
1.49 (UAPON 60×/1.49, Olympus) or a 150× objective with a numerical aperture of 1.45 
(UAPON 60×/1.45, Olympus) was used for TIRF excitation.
The excitation beam was reflected into the objective by a quad-band dichroic mirror (HC-BS 
R405/488/561/635, AHF) and the fluorescence was detected through a quadbandpass filter 
(BrightLine HC 446/523/500/677). For multicolor experiments, a QuadView (QV2, from 
Photometrics) equipped with suitable dichroic beamsplitters (480dcxr, 565dcxr and 640dcxr, 
Chroma) and emission filters (BrightLine HC 438/24, AHF, BrightLine HC 520/35 AHF, 
EmitterHQ 600/30, AHF and BrightLine HC 685/40, Chroma) was utilized to avoid spectral 
cross-talk. Data acquisition was performed with the acquisition software Olympus Xcellence 
rt Version 1.2.
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Fluorescence recovery after photobleaching (FRAP) experiments were performed at 37°C in 
an incubation chamber (Olympus) and using a 150× TIRF objective with a numerical 
aperture of 1.49 (UAPON 150×/1.49, Olympus) for TIR excitation. A circular area with a 
diameter of 8 μm was bleached by 405 nm excitation for 5 s with a laser power of 7.5 mW, 
followed by acquisition with a cycle time of 1–5 s by a 1 mW 488 nm or 561 nm laser 
excitation.
Data analysis
Image analysis and image processing was performed using ImageJ (NIH, Bethesda, MD). 
Image processing comprises cropping, scaling, rotation as well as adjustment of brightness 
and contrast levels. The fluorescence contrast of patterned proteins inside vs. outside the 
pattern was calculated from the average fluorescence intensities of the bait and prey proteins 
obtained from rectangular ROIs using the “Measure” function in ImageJ. The fluorescence 
contrast C of the bait proteins was calculated as
where Ibait,in denotes the mean pixel intensities from selected areas inside the pattern, Ibait,out 
the mean pixel intensities from selected areas outside the pattern and Ibg the background 
intensity from the glass surface obtained from a ROI outside the cells. Cbait reflects the 
relative enrichment of the bait proteins and the maximal enrichment that can be achieved by 
the prey proteins. The contrast of the prey proteins Cprey was obtained from the background 
corrected mean pixel intensities from selected areas inside and outside the pattern as: 
. Since Cprey varies proportional to Cbait, Cprey was corrected to obtain
For quantitative analysis, data were visualized in box plots indicating data distribution of the 
second and third quartile (box), median (line), mean (open squares), and whiskers (1.5× 
interquartile range). Outliers were plotted as individual points.
For analysis of FRAP experiments, a rectangular region of interest within the bleached area 
of the pattern and a rectangular or circular ROI within the bleached area but outside the 
patterned area were chosen for obtaining intensity values per pixel over time, respectively. 
FRAP curves were obtained by the following equation:
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The offset intensity (Foffset) was determined from a ROI outside of the cell and was 
substracted by all intensity values. Free cytoplasmic diffusion in living cell was consistent 
both inside and outside the pattern and its effect to FRAP could be determined as 
(FROIoutside − Foffset). Thus the unbiased fluorescence recovery inside the pattern could be 
obtained by a subtraction of recovery outside the pattern as: (FROIinside − Foffset) − 
(FROIoutside − Foffset). A normalization factor of  was 
implemented in order to correct background photobleaching during FRAP experiments. For 
this purpose, a rectangular ROI in a not-bleached patterned region was assigned as a 
reference and the sequential intensities in this area were normalized to the original one. The 
recovery of the fluorescence intensity was fitted by a simple monoexponential 
function 74,75).
Single molecule ligand binding assay
Single molecule ligand binding experiments were performed in presence of 2 
nM DY647IFNα2 M148A and after an incubation time of 10 minutes by TIRF imaging as 
described previously. All binding experiments were carried out using media complemented 
with oxygen scavenger [0.5mg ml-1 glucose oxidase (Sigma), 0.04 mgml-1 catalase (Roche 
AppliedScience), 5% w/v glucose, 1 μM ascorbic acid and 1μM methyl viologene] in order 
to minimize photobleaching 76. In order to minimize background from non-specifically 
adsorbed dye molecules during single molecule experiments, glass coverslips were coated 
with a poly-L-lysine-graft-(polyethylene glycol) copolymer functionalized with RGD as 
described before77. The assay was performed two times and a representative blot was 
presented. Localization and quantification of individual IFNα2 M148A molecules were 
determined by using the multiple target tracking algorithm (MTT) 78 as described 
previously 79.
IFN FITC labeling and binding affinity assay
Recombinant IFNα2b (ProSpec, Cat#CYT-205) was labeled with fluorescein isothiocyanate 
(FITC) using the SureLINK FITC-Labeling Kit (KPL, Cat# 82-00-01), per the 
manufacturer’s instructions. A conjugate with an optimal molar ratio (F/P) of ~4.1 was used 
for binding affinity experiments. For binding affinity experiments, indicated cell lines were 
incubated with a saturating concentration of FITC-IFNα2b and FITC MFI was measured on 
a BD FACSCanto instrument with standard lasers and optical filters.
Receptors expression analysis
Infected U6A cell lines were trypsinized and incubated with mouse anti-IFNAR1 or 
IFNAR2-FITC antibodies. For the detection of IFNAR1, we used anti-mouse PE secondary 
antibody.
Peptides
THP-1 or KT-1 cells were treated with cell permeable TAT (Trans-Activator of Transcription 
Protein) (GRKKRRQRRRPQ) or USP18 aa 302-313 linker TAT 
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(YELFAVIAHVGMGGGSGRKKRRQRRRPQ) (Eton Bioscience Inc., San Diego, CA) 
(final 10mM in 2%FBS medium) in this study.
Apoptosis assay
Apoptosis was measured by staining with Annexin V-APC and 7-AAD using Annexin V 
apoptosis detection kit (BD) according to the manufacturer’s protocol. Cells were analyzed 
by flow cytometry on a BD FACSCanto with standard lasers and optical filters. The results 
in the paper are the means of the percent of apoptotic cells from three independently infected 
(MIP or MIP-STAT2 CC/DB 3A) or peptide (TAT or USP18 aa 302-313 TAT)-treated cells.
Statistical analyses
Where applicable, statistical significance was determined by using a two-tailed Student’s t- 
test using the statcel2 software (OMS Ltd. Japan). A p value of < 0.05 was considered 
statistically significant. Changes in the interactions between different bait and prey proteins 
in the single molecule ligand binding assay and cell micropatterning experiments as 
determined by the contrast values were statistically analyzed, using the two-sample 
Kolmogorov-Smirnov test. The p values for the contrast values of two samples were 
calculated using MATLAB software. A p value of < 0.05 was considered statistically 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. USP18 interacts with STAT2
(a) Yeast two-hybrid analysis of the direct interaction between USP18 and STAT2. (a),(b) 
Overnight cultures from strains pJ69-4a/pJ69-4alpha carrying two-hybrid plasmids with the 
indicated coding sequences were spotted onto selective media for plasmid maintenance (-
Leu, -Tryp = Ctrl for growth control) and indicators for interactions (-His, in addition to -
Leu, -Tryp).
(b) Immunoblot (IB) analysis of whole cell lysates (WCL) and anti-FLAG 
immunoprecipitates (IP) derived from 293T cells 24 hours after co-transfection with 
plasmids encoding GFP, GFP-USP18, and STAT2-FLAG.
The number for left side of column shows molecular weight (kDa).
(c) GST pull-down assay to demonstrate that the STAT2 directly associate with USP18.
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(d) Immobilization of STAT2 for probing direct interaction with USP18 as depicted in the 
cartoon. U5A cells transfected with mEGFP-USP18 (green channel) and STAT2 intracellular 
fused to a transmembrane domain (TMD) and extracellular fused to mTagBFP as well as 
HaloTag (blue channel). Scale bars: 10 μm. Representative image of 36 cells analyzed. 
Intensity profiles of all channels within the yellow ROI depicted in the merged image (right 
panel). Quantitative analysis of the recruitment of mEGFP-USP18 to micropatterned STAT2 
as determined by the contrast of the fluorescence intensities inside and outside the patterns. 
As negative controls, U5A cells were transfected with mEGFP-USP18 and HaloTag-
mTagBFP-TMD as well as mEGFP and HaloTag-mTagBFP-TMD-STAT2. n: number of 
cells analyzed obtained from two independent experiments. Significance was quantified 
using the two-sample Kolmogorov-Smirnov test. *** P < 0.001. (lower left plot). 
Fluorescence recovery of USP18 recruited to micropatterned STAT2 and monoexponential 
fit of the recovery curve (representative of 8 cells analyzed), lower right plot).
(e) Interaction of endogenous USP18 and endogenous STAT2 in 2fTGH, MDA-MB-231, 
and KT-1 cells. Lysates from cells treated with IFNα (1000 U/ml) for 24 hours were 
immunoprecipitated with IgG or anti-STAT2 and immunoblotted with STAT2 or USP18 
antibodies.
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Figure 2. STAT2 is required for USP18-mediated inhibition of Type I IFN signaling
(a–f) MIP or MIP-USP18 expressing 2fTGH, U1A, U2A, U4A, U5A, and U6A cells were 
treated with IFNα (1000 U/ml) for 15 minutes. The cell lysates were immunoblotted with 
the indicated antibodies.
(g) IB analysis of STAT1 phosphorylation in 2fTGH and U6A cells in the presence or 
absence of (1000 U/ml) IFNα.
(h–i) Stat2−/− MEFs were infected with MIP control (−) or MIP-Usp18 (+) retroviruses, 
either in the presence or absence of rescue with C-terminally FLAG-tagged Stat2 cDNA. 
Where indicated cells were treated with either mouse IFNβ (500 U/ml) for 15 minutes (h) or 
Arimoto et al. Page 24
Nat Struct Mol Biol. Author manuscript; available in PMC 2017 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
30 minutes (i), before cell lysates were collected and analyzed by Western blotting with 
indicated antibodies.
(j) Validation of Stat2 knockdown. Ba/F3 cells were infected with control or Stat2-targeting 
shRNA lentivirus. After 5 days puromycin selection, Stat2 expression was examined by 
Western blotting.
(k) Usp18−/− bone marrow cells were infected with pCX4-bsr control (−) or pCX4-bsr-
Usp18 (+), either in the presence or absence of control (shCtrl) or Stat2-knockdown 
(shStat2–3) shRNA expression. Two days following double drug selection (puromycin and 
blasticidin), cells were either left untreated (−) or treated (+) with mouse IFNβ (500 U/ml) 
for 30 minutes. Cell lysates were collected and analyzed by Western blotting with indicated 
antibodies.
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Figure 3. Both the coiled-coil (CC) and DNA binding (DB) domains of STAT2 are involved in the 
interaction with USP18
(a) A schematic drawing of STAT2 domain structure and the associated deletion mutants 
used in this study. The ability of a given deletion mutant to interact with USP18 (+ or − 
binding) is indicated to the right.
(b–c) IB analysis of WCL and anti-FLAG IP derived from 293T cells 24 hours after co-
transfection with plasmids encoding FLAG-USP18 and either the full-length STAT2-Myc 
(WT) or the indicated deletion mutants.
(d) IB analysis of WCL and anti-FLAG IP derived from 293T cells 24 hours after co-
transfection with plasmids encoding GFP-USP18 and either STAT2-FLAG or the indicated 
deletion mutants. Asterisks are used to indicate non-specific bands. HC = Heavy Chain, LC 
= Light Chain.
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Figure 4. The coiled-coil (CC) and DNA binding (DB) domains of STAT2 are important for 
USP18-mediated inhibition of Type I IFN signaling
(a) U6A cells, stably transduced with control (−) or C-terminally Myc-tagged STAT2 
(STAT2-Myc), were infected with MIP control (−) or MIP-USP18 (+) retrovirus. With or 
without IFNα (1000 U/ml) treatment for 15 minutes cell lysates were collected and 
analyzed by Western blotting with the indicated antibodies.
(b–d) U6A cells, stably transduced to express either full-length STAT2 (STAT2-Myc), or the 
indicated STAT2 deletion mutant (b, STAT2ΔCC-Myc; c, STAT2ΔDB-Myc; d, 
STAT2ΔCC/DB-Myc) with or without IFNα (1000 U/ml) treatment for 15 minutes cell 
lysates were collected and analyzed by Western blotting with the indicated antibodies.
(e) Histograms showing the surface expression of IFNAR1 and IFNAR2 following infection 
with indicated constructs in U6A cell lines.
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Figure 5. STAT2 recruits USP18 to IFNAR2
(a) IB analysis of WCL and anti-FLAG IP derived from U6A cells 24 hours after co-
transfection with plasmids encoding USP18, FLAG-IFNAR2, and increasing amounts of 
STAT2-Myc expression construct. The relative USP18 binding to IFNAR2 from three 
independent experiments was quantified and plotted as the ratio of IFNAR2-bound USP18 to 
total USP18 (right panel). Data are normalized to the maximum binding (lane 4).
(b) Recruitment of USP18 and STAT2 to micropatterned IFNAR2 in STAT2-deficient U6A 
cells as illustrated in the cartoon. U6A cells transfected with HaloTag-mTagBFP-IFNAR2 
and mEGFP-USP18 (USP18 –STAT2) (green channel, left image) and U6A cells transfected 
with HaloTag-mTagBFP-IFNAR2, mEGFP-USP18 and STAT2-TagRFP-T (USP18 +STAT2) 
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(green channel, right image). Representative images of 17 cells analyzed in two independent 
experiments.
(c) Recruitment of USP18 to immobilized IFNAR2 (R2) into micropatterns was quantified 
in U6A cells by determining the contrast of the fluorescence intensities inside and outside 
the patterns. For comparison, constitutive binding of STAT2 (positive control) and cytosolic 
mEGFP (negative control) to micropatterned full length IFNAR2 expressed in U6A cells 
was quantified. n: number of cells analyzed in two independent experiments. Significance 
was quantified using the two-sample Kolmogorov-Smirnov test. *** P < 0.001, n.s., not 
significant.
(d) The C-terminal STAT2 interacting region of IFNAR2 is necessary for recruiting USP18. 
Quantification of recruitment of mEGFP-USP18 co-expressed with STAT2-TagRFP-T to 
immobilized HaloTag-IFNAR2 or C-terminally truncated HaloTag-IFNAR2 (R2Δ375) in 
Hela cells. As negative controls, HeLa cells were transfected with cytosolic mEGFP or 
TagRFP-T, respectively. n: number of cells analyzed in two independent experiments. 
Significance was quantified using the two-sample Kolmogorov-Smirnov test. *** P < 0.001, 
n.s. not significant.
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Figure 6. STAT2-USP18 interaction regulates ternary complex assembly of the Type I IFN 
receptor
(a) Binding of DY647IFNα2 M148A bound to the IFNAR at the surface of U6A cells 
expressing STAT2-TagRFP-T (top-left), USP18-mEGFP (top-right) or both (bottom-left). 
The images are superimpositions of single molecule localizations from 100 consecutive 
frames. Scale bars: 10 μm. Representative images of 13–18 cells analyzed for each 
condition.
(b) Comparison of the density of DY647IFNα2 M148A bound to cell surface IFNAR of U6A 
cells expressing STAT2, USP18 or both proteins. Furthermore, protein with only STAT2 CC 
domain or with only CC and DB domains of STAT2 were also used in the assay. As a 
control, localizations of DY647IFNα2 M148A on the surface of U6A cells transfected with 
mEGFP were quantified. Data were acquired in two independent experiments, n indicates 
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number of cells analyzed for each condition. Significance was quantified using the two-
sample Kolmogorov-Smirnov test. *** P < 0.001; **P < 0.01; * P < 0.05, n.s. not 
significant.
(c) Relative amount of FITC-labeled IFNα bound to the surface of U6A cells was examined 
by flow cytometry. Cells are transduced to express the indicated constructs. Data are 
normalized to the mean fluorescence intensity (MFI) of U6A cells in the absence of STAT2 
and USP18.
(d) U6A cells, stably transduced with control (−) or C-terminally Myc-tagged STAT2 Y690F 
mutant (STAT2 Y690F), were infected with MIP (−) or MIP-USP18 (+) retrovirus. With or 
without IFNα (1000 U/ml) treatment for 15 minutes, cell lysates were analyzed by Western 
blotting.
(e) Relative amount of FITC-labeled IFNα bound to the surface of U6A cells was examined 
by flow cytometry. Data are normalized to the MFI of U6A cells in the absence of STAT2 
and USP18. Data of figure 6 (c) and (e) are presented as mean ± S.E.M. for three 
independent experiments. ***P < 0.001., n.s. not significant.
(f) Model of USP18-STAT2 regulating IFN response.
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Figure 7. Inhibiting negative feedback regulation of USP18 by targeting its interaction with 
STAT2
(a) 293T cells were co-transfected with plasmids encoding STAT1-FLAG, FLAG-USP18 
and either STAT2 CC/DB-Myc or the mutant STAT2 CC/DB L227A R409A K415A-Myc 
(3A). Following treatment with IFNα (1000 U/ml) for 15 minutes as indicated cell lysates 
were collected and immunoblotted with indicated antibodies. The ratio of p-STAT1/total 
STAT1 was quantified by LI-COR Odyssey system.
(b) Cells indicated in Fig. 7a were treated with IFNα (1000 U/ml) for 12 hours and then 
expression of GBP1 was analyzed by RT q-PCR. Data represents mean ± S.D. for two 
independent experiments.
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(c) THP-1 cells transduced with either MIP control (−) or MIP-STAT2 CC/DB 3A (3A) were 
treated with IFNα (1000 U/ml) for 48 hours and then Annexin V positive cells were 
analyzed by flow cytometry. Data represents mean ± S.E.M. for three independently 
generated stable cell lines. **P < 0.01.
(d) THP-1 and KT-1 cells were treated with TAT or USP18 aa 302-313 TAT peptide. Five 
hours after peptide treatment, IFNα (1000 U/ml) was added for the indicated time and cells 
were analyzed by Western blotting. The ratio of p-STAT1/total STAT1 from three 
independent experiments was quantified (right panel). Data are presented as mean +/c 
S.E.M. of three independent experiments. *P < 0.05.
(e) TAT- or USP18 aa 302-313 TAT peptide-treated THP-1 and KT-1 cells were incubated 
with IFNα (1000 U/ml) for 48 hours and then Annexin V positive cells were analyzed by 
flow cytometry. Data are presented as mean +/− S.E.M. of three independent experiments. 
**P < 0.01.
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